$1.28
+0.05
(+4.07%)▲
2.34%
Downside
Day's Volatility :3.85%
Upside
1.55%
13.28%
Downside
52 Weeks Volatility :77.8%
Upside
74.4%
Period | Barinthus Biotherapeutics Plc | Index (Russel 2000) |
---|---|---|
3 Months | -35.68% | 0.0% |
6 Months | -51.7% | 0.0% |
1 Year | -30.05% | 0.0% |
3 Years | -91.43% | -22.3% |
Market Capitalization | 50.5M |
Book Value | $4.0 |
Earnings Per Share (EPS) | -1.64 |
Wall Street Target Price | 5.5 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -19.7% |
Return On Equity TTM | -34.13% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | 44.7M |
EBITDA | -65.6M |
Diluted Eps TTM | -1.64 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.62 |
EPS Estimate Next Year | -1.48 |
EPS Estimate Current Quarter | -0.41 |
EPS Estimate Next Quarter | -0.4 |
What analysts predicted
Upside of 329.69%
Sell
Neutral
Buy
Barinthus Biotherapeutics Plc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Barinthus Biotherapeutics Plc | -7.91% | -51.7% | -30.05% | -91.43% | -91.38% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Barinthus Biotherapeutics Plc | NA | NA | NA | -1.62 | -0.34 | -0.2 | NA | 4.0 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Barinthus Biotherapeutics Plc | Buy | $50.5M | -91.38% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Barinthus Biotherapeutics Plc
Revenue is up for the last 2 quarters, 334.0K → 5.36M (in $), with an average increase of 93.8% per quarter
Netprofit is down for the last 2 quarters, -15.48M → -16.94M (in $), with an average decrease of 9.5% per quarter
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 67.2%
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 160.6%
M&G PLC
Alphabet Inc
SC China Holding Ltd
DC Funds, LP
BlueCrest Capital Management Ltd.
Baird Financial Group, Inc.
vaccitech is a spin-out company from the university of oxford’s jenner institute, one of the oldest and most renowned vaccine research centres in the world. the company has been formed around two viral vector vaccines, one to prevent influenza and the other to treat prostate cancer. viral vector vaccines are particularly good at treating some of the most recalcitrant illnesses. the underlying technology is built on years of experience perfecting viral vector vaccine technology across multiple indications. the company’s protected chimpanzee adenovirus technology is the best way to generate t-cell responses and thereby generate lasting cell-mediated immunity. the assets are already in the clinic with very promising initial results. the founders of the company are professor adrian hill (director of the jenner institute) and professor sarah gilbert (lead in influenza and mers), who combine their exceptional scientific skills with regulatory and manufacturing experience. this autumn, vaccit
Organization | Barinthus Biotherapeutics Plc |
Employees | 130 |
CEO | Mr. William J. Enright MBA |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$1.28
+4.07%
Keyarch Acquisition Corp
$1.28
+4.07%
Connexa Sports Technologies Inc
$1.28
+4.07%
Us Value Etf
$1.28
+4.07%
First Wave Biopharma Inc
$1.28
+4.07%
Global X Msci Next Emerging
$1.28
+4.07%
Fat Projects Acquisition Corp
$1.28
+4.07%
Capital Link Global Fintech
$1.28
+4.07%
Applied Uv Inc
$1.28
+4.07%